The half hemolysis rate (HC50) test is an in vitro assay that determines the concentration of a test substance needed to lyse 50% of a standardized red blood cell suspension, providing a quantitative indicator of membrane-damaging and eye irritation potential. This technical guide explains the complete HC50 testing process, covering sample types, testing methods, calculation procedures, and typical applications in cosmetic and chemical safety evaluation.
Technical Overview
The half hemolysis rate test, commonly expressed as HC50 (half maximal hemolysis concentration), is an in vitro toxicology assay that measures the ability of a test substance to disrupt erythrocyte cell membranes. Because damage to red blood cell membranes correlates closely with damage to the corneal and mucous membrane epithelium, the HC50 value serves as a widely accepted screening endpoint for predicting the eye irritation potential of surfactants, cosmetic formulations, and other chemical products. The test is fully animal-free at the endpoint level, using only freshly collected blood, which makes it a key component of tiered, non-animal safety assessment strategies.
During the assay, a series of diluted test substance solutions is mixed with a standardized suspension of red blood cells. Substances that damage the erythrocyte membrane cause hemoglobin to leak into the surrounding medium. After centrifugation, the released hemoglobin in the supernatant is quantified spectrophotometrically at approximately 540 to 575 nm. The hemolysis rate at each concentration is calculated against positive and negative controls, and the HC50 value is interpolated from the resulting concentration-response curve. The methodology is aligned with the general principles of internationally recognized in vitro alternative test guidelines and with hemocompatibility frameworks such as ISO 10993-4, GB/T 16886.4, and ASTM F756.
- Endpoint: concentration of test substance producing 50% hemolysis (HC50)
- Principle: erythrocyte membrane disruption and hemoglobin release
- Detection: UV-Visible spectrophotometry of free hemoglobin
- Output: quantitative dose-response curve and HC50 classification
Testing Samples
Cosmetic Finished Products
Rinse-off and leave-on cosmetic products with surfactant-based or membrane-active formulations are the most common samples for HC50 testing. These include shampoos, facial cleansers, body washes, hand soaps, makeup removers, and micellar waters. The test helps formulators verify the mildness claims of finished products and screen out potentially irritating batches before market release.
Cosmetic Raw Materials and Surfactants
Individual surfactants such as anionic, nonionic, amphoteric, and cationic surfactants, along with preservatives, solubilizers, and plant extracts, are routinely evaluated. HC50 testing supports raw material selection, supplier comparison, and the development of milder surfactant blends by ranking membrane-disrupting potency on a quantitative scale.
Household and Industrial Chemicals
Detergents, disinfectants, cleaning agents, and other household or industrial chemicals that may accidentally contact the eyes or mucous membranes are tested to support hazard classification and labeling decisions, as well as occupational safety assessments.
Blood-Contacting Medical Device Materials
For medical devices that contact circulating blood, hemolysis testing in accordance with ISO 10993-4, GB/T 16886.4, and ASTM F756 is performed using either the direct contact method or the extract method. While this biocompatibility test reports a hemolysis index rather than an HC50 value, it shares the same spectrophotometric detection principle and is often offered alongside HC50 testing by accredited third-party laboratories.
Testing Items
A standard HC50 test report issued by an accredited third-party laboratory typically includes the following items:
- Hemolysis rate at each tested concentration, expressed as a percentage
- Full concentration-response (dose-effect) curve with semi-logarithmic plotting
- Calculated HC50 value with confidence interval, where applicable
- Positive control validation result (for example, Triton X-100 or deionized water inducing complete hemolysis)
- Negative control validation result (phosphate-buffered saline or physiological saline with minimal background hemolysis)
- Optional hemoglobin denaturation assessment for materials with strong protein-binding activity
- Classification of irritation potential based on predefined HC50 threshold bands
Testing Methods
Sample Preparation
The test substance is diluted in phosphate-buffered saline (PBS) or physiological saline to produce a geometric series of concentrations, typically spanning at least five to seven dilution levels designed to bracket the anticipated 50% hemolysis point. Liquid samples are diluted directly, while solid or viscous samples are pre-dissolved or homogenized to ensure consistent exposure. For medical device extracts, extraction is carried out in physiological saline under conditions consistent with ISO 10993-12 sample preparation guidance.
Preparation of the Red Blood Cell Suspension
Freshly collected anticoagulated or defibrinated blood, typically of rabbit or human origin obtained under an approved blood collection protocol, is washed at least three times with PBS by centrifugation until the supernatant is clear. The packed erythrocytes are then resuspended in PBS to a defined cell concentration, commonly in the range of 2% to 5%, and the suspension is used promptly on the day of preparation to ensure cell viability.
Exposure and Incubation
Equal volumes of each test dilution are mixed with the red blood cell suspension in duplicate or triplicate test tubes. The mixtures are incubated at room temperature or at 37 degrees Celsius for a defined exposure period, commonly 10 to 60 minutes with gentle inversion at intervals to maintain uniform contact. Parallel tubes containing only PBS (negative control) and a known hemolytic agent such as Triton X-100 or deionized water (positive control representing 100% hemolysis) are processed identically.
Centrifugation and Spectrophotometric Measurement
Following incubation, all tubes are centrifuged to pellet intact erythrocytes and debris. The supernatant from each tube is transferred to a clean cuvette or microplate, and the absorbance of released hemoglobin is measured at approximately 540 to 575 nm against a reagent blank. Test substances that are inherently colored or turbid are corrected using substance blanks without red blood cells to eliminate spectral interference.
Calculation of Hemolysis Rate and HC50
The hemolysis rate at each concentration is calculated using the standard formula: hemolysis rate (%) equals the absorbance of the sample supernatant minus the absorbance of the negative control, divided by the absorbance of the positive control minus the absorbance of the negative control, multiplied by 100. The hemolysis rates are plotted against the logarithm of concentration, and the HC50 value is derived by interpolation or non-linear regression at the 50% hemolysis intercept. A monotonic dose-response relationship and validated control performance are required for the run to be accepted.
Result Interpretation and Classification
A lower HC50 value indicates stronger membrane-disrupting capacity and therefore higher irritation potential. Typical classification schemes used by accredited laboratories assign categories such as severe, moderate, mild, and minimal based on defined HC50 threshold ranges, although the exact cut-off values may vary with the product category and the applicable regulatory framework. Results are always interpreted together with the control validation data and, where relevant, with complementary in vitro endpoints as part of a weight-of-evidence approach.
Applications
HC50 testing is applied across product development, quality control, and regulatory compliance workflows. Its quantitative nature makes it particularly valuable for comparative studies and formulation optimization.
- Screening cosmetic formulations and surfactants for eye irritation potential without animal testing
- Supporting mildness claims and comparative advertising claims for rinse-off products
- Ranking raw materials and supplier grades by membrane toxicity during formulation development
- Providing supporting data for safety dossiers and regulatory notifications of cosmetics and household chemicals
- Assisting hazard classification and labeling decisions for industrial and consumer chemical products
- Complementing ISO 10993-4, GB/T 16886.4, and ASTM F756 hemocompatibility evaluations for blood-contacting medical devices
- Batch-to-batch quality control of surfactant-based products during scale-up and production
FAQ
What is the difference between HC50 and the ISO 10993-4 hemolysis test?
The HC50 test determines the concentration of a test substance that lyses 50% of a red blood cell suspension, producing a quantitative potency value used mainly for irritation screening of chemicals and cosmetics. The ISO 10993-4 hemolysis test evaluates whether a medical device material or its extract causes hemolysis under defined contact conditions and reports a hemolysis index, commonly with an acceptance limit of 5%. Both tests rely on the same hemoglobin-release detection principle but serve different regulatory purposes.
How much sample is required for an HC50 test?
In most cases, 10 to 50 milliliters of liquid sample or 10 to 50 grams of solid sample are sufficient to cover the full dilution series, substance blanks, and potential repeat runs. Laboratories may request additional material for colored, turbid, or highly viscous samples that require interference correction or additional dilution adjustments.
What is the typical turnaround time?
The bench work itself is completed within one to two days because the assay uses fresh blood and short incubation periods. Including blood scheduling, data analysis, and report issuance, accredited third-party laboratories typically deliver results within five to ten working days after sample receipt.
Can the HC50 test fully replace the rabbit eye irritation test?
The HC50 test is a powerful screening tool, but it is not intended to stand alone as a complete replacement for all in vivo endpoints. It is normally used within a tiered testing strategy, combined with other in vitro methods such as reconstructed human tissue models, to build a weight-of-evidence safety assessment that minimizes or eliminates animal testing.
What quality criteria must a valid test run meet?
The negative control must show minimal background hemolysis, the positive control must achieve near-complete hemolysis, the concentration series must produce a monotonic dose-response, and all replicates must fall within the accepted coefficient of variation. Runs failing these criteria are rejected and repeated to ensure the reliability of the reported HC50 value.
